This site is intended for healthcare professionals
Multiple Myeloma Awareness: Bone marrow aspirate cytology of multiple myeloma, a type of bone marrow cancer of malignant plasma cells, associated with bone pain, bone fractures and anemia
Hot topics in RRMM: COMy 2024 expert picks

Transcript: Treatment advances in RRMM

Last updated: 25th Jun 2024
Published:25th Jun 2024

Dr Hira Mian

Interview recorded Jun 2024. All transcripts are created from interview footage and directly reflect the content of the interview at the time. The content is that of the speaker and is not adjusted by Medthority.

So again, in relapse refractory multiple myeloma, I think, you know, we're seeing, again, lots of activity with T-cell redirecting therapies. We're seeing a lot of these therapies that we're used to seeing some of the data in greater than three or four lines of treatment. We're seeing that data being moved in earlier lines of treatment. So we already, across the world, in many parts of the world, cilta-cel, for example, is being moved to an earlier line of treatment and there's additional clinical trials that will in fact be evaluating in first line of treatment.

So I think in this relapse refractory setting, we're seeing a shift in a lot of those therapies that have been very exciting in moving it earlier. You know, it remains to be seen how the efficacy and durability is as well as some of the toxicity. So even at this COMy, there was a lot of discussion around what toxicity is tolerable or should be accepted, especially as you move some of these therapies up front. So I would say in the next few years, you know, we'll see a lot of activity probably in that one to three prior lines or potentially even be in the newly diagnosed setting as all of these therapies get moved upfront.

Watch the video

Welcome:

This content has been developed independently of the sponsor, Takeda, which has had no editorial input into the content. Medthority received educational funding from the sponsor in order to help provide its healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content. Symposium content is intended for healthcare professionals only.